HomeGeneticsConditionAge-related macular degeneration
Back to Condition
Age-related macular degeneration
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Age-related macular degeneration

Age-related macular degeneration is a common eye disease that causes central vision loss in older adults by damaging the macula, the part of the eye responsible for detailed vision.

Overview

Age-related macular degeneration (AMD) is a leading cause of vision loss in older people. While subtle abnormalities may appear in a person's forties or fifties, distorted vision and vision loss typically become noticeable in the sixties or seventies and worsen over time.

Types of AMD

  • Dry form: Accounts for 85 to 90 percent of cases. It is characterized by the buildup of yellowish deposits called drusen beneath the retina. The most advanced stage is geographic atrophy, where areas of the macula waste away.
  • Wet form: Occurs in 10 to 15 percent of cases. It involves the growth of abnormal, fragile blood vessels underneath the macula that leak blood and fluid, causing rapid and severe vision loss.

Causes and Risk Factors

AMD results from a combination of genetic and environmental factors:

  • Genetic factors: Many genes involved in the complement system (part of the immune response), such as the CFH gene, contribute to risk. Variations in the 10q26 region of chromosome 10, including the ARMS2 and HTRA1 genes, are also associated with increased risk.
  • Environmental factors: Age is the most significant risk factor. Other factors include smoking, high blood pressure, heart disease, obesity, exposure to ultraviolet (UV) rays, and diets high in fat or low in antioxidants and zinc.

Inheritance

AMD does not have a clear-cut pattern of inheritance, though it often runs in families. Approximately 15 to 20 percent of affected individuals have at least one first-degree relative with the condition.

Frequently Asked Questions

Treatment is indicated as soon as neovascular (wet) changes are confirmed by OCT or fluorescein angiography, because vision can deteriorate rapidly. First‑line therapy is intravitreal anti‑VEGF injections (e.g., ranibizumab, aflibercept, or bevacizumab) given monthly or per a treat‑and‑extend schedule. Photodynamic therapy or laser photocoagulation are used only in select cases.
bsolutely. Smoking doubles the risk of progression to advanced AMD. Quitting reduces oxidative stress and improves vascular health, which can slow disease progression even after diagnosis.
Early signs include subtle difficulty reading small print, needing brighter light for tasks, or noticing straight lines that appear wavy (metamorphopsia). If any of these occur, especially in someone over 50, schedule a dilated retinal exam promptly.
Yes. Clinical trials support a daily combination of vitamin C (500 mg), vitamin E (400 IU), lutein (10 mg), zeaxanthin (2 mg), zinc (80 mg as zinc oxide), and copper (2 mg) (the AREDS2 formula). A diet rich in leafy greens, fish, and low in saturated fat also helps maintain retinal health.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab